e-learning
resources
Vienna 2009
Monday, 14.09.2009
Biological and clinical markers in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Systemic inflamation and bronchial dysplasia in risk lung cancer subjects
N. Rodriguez, F. Andreo, J. Sanz, E. Monsó, L. Setó, J. Sauleda, F. De Borja, A. Noguera, A. Rosell (Vilafranca del Penedès, Badalona, Palma de Mallorca, Spain)
Source:
Annual Congress 2009 - Biological and clinical markers in lung cancer
Session:
Biological and clinical markers in lung cancer
Session type:
Thematic Poster Session
Number:
2669
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Rodriguez, F. Andreo, J. Sanz, E. Monsó, L. Setó, J. Sauleda, F. De Borja, A. Noguera, A. Rosell (Vilafranca del Penedès, Badalona, Palma de Mallorca, Spain). Systemic inflamation and bronchial dysplasia in risk lung cancer subjects. Eur Respir J 2009; 34: Suppl. 53, 2669
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
COPD as an independent risk factor for lung cancer in patients with bronchial squamous dysplasia
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Angiogenesis in bronchial biopsies of symptomatic smokers with and without lung cancer
Source: Annual Congress 2008 - Basic science in asthma and COPD II
Year: 2008
Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort
Source: Eur Respir J, 49 (5) 1601162; 10.1183/13993003.01162-2016
Year: 2017
Investigation of biomarkers for pulmonary carcinomatous lymphangitis in patients with lung cancer
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Pecularities of lung cancer in patients with COPD
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Coexistence of COPD in lung cancer patients
Source: Eur Respir J 2001; 18: Suppl. 33, 66s
Year: 2001
Role of systemic and bronchial oxidative stress and inflammation in lung cancer predisposition in patients with COPD
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016
Year: 2018
Incidence of lung cancer among COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 494s
Year: 2005
Adenocarcinoma of the lung mimicking inflammatory lung disease with honeycombing
Source: Eur Respir J 2004; 24: 502-505
Year: 2004
Chronic obstructive pulmonary disease is an independent risk factor for nonsmall cell lung cancer in smokers
Source: Eur Respir J 2002; 20: Suppl. 38, 254s
Year: 2002
Emphysema, airway obstruction and prognosis in lung cancer
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010
Systemic inflammation and pulmonary hypertension in patients with bronchial asthma
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
The Asian experience in co-existing lung cancer and interstitial lung disease
Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!
Year: 2018
Clubbing in patients with fibrotic interstitial lung diseases
Source: International Congress 2017 – ILDs: clinical problems
Year: 2017
Bilateral lung cancer with COPD or metastatic disease
Source: International Congress 2016 – CC4 Major challenges in thoracic surgical oncology
Year: 2016
Comparison of clinical features between patients of lung cancer with combined pulmonary fibrosis and emphysema syndrome and those with interstitial pneumonia
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
Management of concomitant COPD in patients with lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Lung nodules in a lung cancer screening program: incidence density of lung cancer in patients with COPD and/or emphysema
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009
Prevalence of bronchiectasis in a lung cancer screnning program
Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept